HIF-2α inhibitor shows promise in renal cell carcinoma

The results of a first-in-human phase I clinical trial with a new drug called PT2385 were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last week. PT2385 is an inhibitor of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other […]

read more
Showing the single result